Table III.
TSP-1, TGF-β and PPAR-γ expression levels by glioma grade.
| Indicators | Groups | Cases (n) | Negative (−) | Mild positive (+) | Positive (++) | Intense positive (+++) | Total positive rate (%) | P1-value (χ2) | Intense positive rate (%) | P2-value (χ2) |
|---|---|---|---|---|---|---|---|---|---|---|
| TSP-1 | Low-grade | 51 | 11 | 3 | 18 | 19 | 78.4 | 0.00a (11.2) | 37.3 | 0.00a (13.8) |
| High-grade | 48 | 26 | 13 | 6 | 3 | 45.8 | 6.3 | |||
| TGF-β | Low-grade | 51 | 29 | 11 | 8 | 3 | 43.1 | 0.00a (29.0) | 5.9 | 0.00a (29.7) |
| High-grade | 48 | 3 | 3 | 15 | 27 | 93.8 | 56.3 | |||
| PPAR-γ | Low-grade | 51 | 3 | 8 | 19 | 21 | 94.1 | 0.00a (33.6) | 41.2 | 0.00a (16.4) |
| High-grade | 48 | 29 | 8 | 8 | 3 | 39.6 | 6.3 |
a
P<0.01 vs. high-grade group.
TSP-1, thrombospondin-1; TGF-β, transforming growth factor-β; PPAR-γ, peroxisome proliferator-activated receptor-γ.